Survey on Divalproex Sodium Use: Insights into Epilepsy Treatment

Table of Content

INTRODUCTION

Epilepsy, a chronic neurological disorder characterized by recurrent, unprovoked seizures, affects approximately 50 million people globally, making it one of the most common neurological conditions worldwide (1). The disorder significantly impacts patients' quality of life, with implications for their social, educational, and occupational opportunities (2). Effective management of epilepsy aims to achieve sustained seizure control while minimizing side effects, which can be particularly challenging given the diverse etiologies and patient responses to treatment (3).

Divalproex sodium, a widely used antiepileptic drug (AED), is recognized for its broad-spectrum efficacy in managing various seizure types, including absence, complex partial, and generalized tonic-clonic seizures (4). It works primarily by increasing gamma-aminobutyric acid (GABA) levels in the brain, stabilizing neuronal activity and preventing abnormal electrical discharges that cause seizures (5). Additionally, Divalproex sodium is also used in managing bipolar disorder and migraine prophylaxis, further highlighting its versatility in neurological care (6).

Despite its effectiveness, Divalproex sodium use is not without challenges. Potential side effects, such as weight gain, gastrointestinal disturbances, and hepatotoxicity, can influence adherence and treatment outcomes (7). Furthermore, its teratogenic risks necessitate careful consideration in women of childbearing age, requiring clinicians to weigh the benefits against potential harm (8).

Understanding real-world prescribing patterns, clinicians' experiences, and patient outcomes associated with Divalproex sodium is critical in optimizing its use. While clinical trials provide valuable efficacy and safety data, real-world

evidence captures the complexities of diverse patient populations and comorbid conditions, offering insights that can enhance clinical decision-making (9).

This study aims to explore healthcare professionals' experiences with Divalproex sodium in epilepsy management. It seeks to provide a comprehensive understanding of its perceived effectiveness, safety, and barriers to optimal use, contributing to improved patient outcomes and more informed treatment strategies (10).

RATIONALE OF THE STUDY

Epilepsy poses significant challenges in neurological care, necessitating effective and well-tolerated treatment options to ensure optimal seizure control. While Divalproex sodium has established efficacy across various seizure types, its real-world application in diverse patient populations remains underexplored.

Real-world data are essential to evaluate how clinicians perceive and utilize Divalproex sodium in everyday practice, particularly in managing comorbidities, addressing side effects, and navigating specific concerns such as teratogenicity. This study seeks to address these gaps by investigating clinician experiences, prescribing patterns, and patient outcomes associated with Divalproex sodium, ultimately contributing to evidence-based advancements in epilepsy care.

STUDY OBJECTIVE

The primary objective of this study is to evaluate the real-world usage, effectiveness, and tolerability of Divalproex sodium in epilepsy management. Specifically, the study aims to:

1. **Assess Clinician Awareness and Familiarity:** Determine the extent of clinicians' knowledge about Divalproex sodium's indications, mechanism of action, and safety profile.
2. **Evaluate Prescribing Patterns:** Identify how frequently and under what circumstances Divalproex sodium is prescribed compared to other AEDs.
3. **Analyze Effectiveness and Safety:** Explore clinicians' perceptions of Divalproex sodium's efficacy in managing seizures and its tolerability in diverse patient populations.
4. **Understand Patient Demographics:** Examine the characteristics of patients prescribed Divalproex sodium, including seizure types, age groups, and comorbid conditions.
5. **Identify Barriers and Opportunities:** Investigate challenges in prescribing Divalproex sodium, such as concerns about side effects, adherence, or cost, and potential strategies to address these barriers.

METHODS

The study employed a survey-based method, utilizing a structured questionnaire distributed among healthcare professionals involved in epilepsy management.

1. **Survey Design**: The questionnaire covered key areas, including familiarity with Divalproex sodium, prescribing patterns, effectiveness, safety, and patient demographics. It was reviewed and validated by experts in neurology and epilepsy care to ensure accuracy, relevance, and comprehensiveness.

2. **Participant Recruitment**: The survey targeted neurologists, epileptologists, and general practitioners experienced in managing epilepsy across various regions. Participants were selected based on their clinical expertise and willingness to provide insights into Divalproex sodium use.

3. **Data Collection**: Responses were collected over a three-month period via physical and electronic survey forms. The data were anonymized to protect participants' confidentiality and encourage unbiased feedback.

4. **Data Analysis**: The collected data were analyzed using descriptive and comparative statistical methods to identify trends in prescribing practices, effectiveness ratings, and safety concerns. Subgroup analyses were conducted to explore variations based on clinician specialty, patient demographics, and treatment settings.

5. **Ethical Considerations**: The study adhered to ethical guidelines for research, including obtaining informed consent from all participating clinicians. The confidentiality of respondents and patient-related data was maintained throughout the study.

RESULTS

A total of 105 HCPs participated in the survey. Below is the summary of the responses.

1. **In your clinical practice, for which conditions would you primarily prescribe Divalproex?**

   A. Epilepsy

   B. Mania

   C. Migraine prophylaxis

   D. All of the above



- **Epilepsy (33%):** A significant portion of healthcare professionals primarily prescribe Divalproex for epilepsy.
- **Mania (48%):** The majority of professionals use Divalproex primarily for the treatment of mania.
- **Migraine Prophylaxis (19%):** A smaller group of professionals prescribe Divalproex primarily for migraine prevention.

2. In your clinical practice, how would you prefer to prescribe Divalproex Sodium in the treatment of Epilepsy?

A. As a Monotherapy

B. In Combination therapy with other antiepileptics

C. As a second line therapy



- **As a Monotherapy (90%):** The vast majority of healthcare professionals prefer to prescribe Divalproex Sodium as a monotherapy for the treatment of epilepsy.
- **In Combination Therapy with Other Antiepileptics (10%):** A smaller group of professionals prefer using Divalproex Sodium in combination with other antiepileptics.

3. In your clinical practice, what percentage of epileptic patients do you estimate to achieve seizure freedom with Divalproex monotherapy?

A. >75%

B. 50-75%

C. 25-50%

D. <25%



- **>75% (76%):** The majority of healthcare professionals estimate that more than 75% of epileptic patients achieve seizure freedom with Divalproex monotherapy.
- **50-75% (24%):** A smaller group of professionals estimate that 50-75% of patients achieve seizure freedom with Divalproex monotherapy.

4. According to your opinion, what is the optimal duration of Divalproex therapy for the treatment of focal onset seizures?

A. 6 months

B. 1 year

C. 2 years

D. Depending upon symptom control



- **6 Months (81%):** The majority of healthcare professionals consider six months as the optimal duration for Divalproex therapy in treating focal onset seizures.
- **1 Year (19%):** A smaller group of professionals believe one year is the optimal duration of therapy.

5. According to your opinion, for which type of epilepsy would you prescribe Divalproex most often?

A. Generalized tonic – clonic seizure

B. Absence seizure

C. Partial onset seizures

D. Lennox – Gastaut syndrome



- **Generalized Tonic-Clonic Seizure (24%):** A smaller group of healthcare professionals prescribe Divalproex most often for generalized tonic-clonic seizures.
- **Absence Seizure (57%):** The majority of professionals most frequently prescribe Divalproex for absence seizures.
- **Partial Onset Seizures (19%):** A smaller group of professionals use Divalproex most often for partial onset seizures.

6. **According to your opinion, how effective do you find Divalproex compared to other antiepileptic drugs in managing epilepsy?**

A. More effective

B. Equally effective

C. Less effective



- **More Effective (90%):** The vast majority of healthcare professionals find Divalproex more effective compared to other antiepileptic drugs in managing epilepsy.
- **Equally Effective (5%):** A small group of professionals consider Divalproex equally effective as other antiepileptic drugs.
- **Less Effective (5%):** Another small group of professionals find Divalproex less effective than other antiepileptic drugs.

7. According to your opinion, which of the following adverse effect(s) is/are commonly associated with Divalproex sodium use?

A. Bradycardia

B. Hyperglycemia

C. Alopecia

D. Thrombocytopenia



- **Bradycardia (52%):** The majority of healthcare professionals identify bradycardia as a common adverse effect associated with Divalproex sodium use.
- **Hyperglycemia (24%):** A significant portion of professionals associate hyperglycemia with the use of Divalproex sodium.
- **Alopecia (14%) & Thrombocytopenia (10%):** A smaller group of professionals consider alopecia & thrombocytopenia a common adverse effect of Divalproex sodium.

8. In your clinical experience, have you observed any severe side effects in patients administering divalproex?

A. Yes

B. No



- **Yes (86%):** A large majority of healthcare professionals have observed severe side effects in patients administering Divalproex.
- **No (14%):** A smaller group of professionals have not observed any severe side effects with Divalproex administration.

9. **In your clinical practice, how would you manage the common side effects of Divalproex in your patients?**

A. Dose reduction

B. Discontinuation of Divalproex

C. Switching to different medication

D. Symptomatic treatment



- **Dose Reduction (62%):** The majority of healthcare professionals manage common side effects of Divalproex by reducing the dose.
- **Discontinuation of Divalproex (19%):** A smaller group opts to discontinue the medication to manage side effects.
- **Switching to a Different Medication (19%):** An equal portion of professionals choose to switch to a different medication.

10. **In your opinion, which laboratory parameter should be monitored regularly in patients taking Divalproex sodium?**

A. Liver function test

B. Renal function test

C. Thyroid function test

D. Complete blood count



- **Liver Function Test (33%):** A significant portion of healthcare professionals recommend regular monitoring of liver function in patients taking Divalproex sodium.
- **Renal Function Test (48%):** The majority prioritize monitoring renal function regularly.
- **Complete Blood Count (19%):** A smaller group of professionals recommend regular monitoring of complete blood count in these patients.

11. In your clinical practice, how often would you monitor liver function tests (LFT) in patients on Divalproex therapy?

A. Every month

B. Every 3 months

C. Every 6 months

D. Annually

E. As and when required



- **Every Month (67%):** The majority of healthcare professionals monitor liver function tests every month in patients on Divalproex therapy.
- **Every 3 Months (9%):** A smaller group monitors liver function tests every three months.
- **Every 6 Months (24%):** A few professionals opt to monitor liver function tests every six months.

12. In your opinion, which of the following factors may influence the dosing of Divalproex sodium?

A. Age

B. Weight

C. Renal function

D. All of the above



- **Age (67%):** The majority of healthcare professionals consider age as a factor that influences the dosing of Divalproex sodium.
- **Weight (14%):** A smaller group believes that weight influences the dosing of Divalproex sodium.
- **Renal Function (19%):** Some professionals consider renal function as a factor that may affect the dosing of Divalproex sodium.

13. **In your clinical practice, how would you rate compliance of epileptic patients who are on Divalproex therapy?**

A. Excellent compliance

B. Good compliance

C. Moderate compliance

D. Poor compliance



- **Excellent Compliance (67%):** The majority of healthcare professionals rate the compliance of epileptic patients on Divalproex therapy as excellent.
- **Good Compliance (24%):** A smaller group rates the compliance as good.
- **Moderate Compliance (9%):** A few professionals rate the compliance as moderate.

14. **In your opinion, what is the main advantage of using extended-release formulations of Divalproex sodium?**

A. Lower incidence of adverse effects

B. More rapid onset of action

C. Simplified dosing schedule

D. Reduced risk of drug interaction



- **Lower Incidence of Adverse Effects (71%):** Most healthcare professionals believe the main advantage of extended-release Divalproex sodium is a lower incidence of adverse effects.
- **More Rapid Onset of Action (19%):** A smaller group believes that extended-release formulations offer a more rapid onset of action.
- **Simplified Dosing Schedule (10%):** A few professionals consider the simplified dosing schedule as the main advantage of extended-release formulations.

15. According to your opinion, which of the following is a contraindication for the use of Divalproex sodium?

A. History of Pancreatitis

B. History of Migraines

C. History of Asthma

D. History of Hypertension



- **History of Pancreatitis (14%):** A smaller group of professionals consider a history of pancreatitis a contraindication for using Divalproex sodium.
- **History of Migraines (38%):** A significant portion of professionals consider a history of migraines a contraindication for Divalproex sodium use.
- **History of Hypertension (48%):** Nearly half of the professionals consider a history of hypertension a contraindication for Divalproex sodium use.

16. According to your opinion, which of the following drugs may interact with Divalproex sodium, potentially necessitating dosage adjustments?

A. Carbamazepine

B. Warfarin

C. Aspirin

D. All of the above



- **Carbamazepine (76%):** The majority of healthcare professionals believe that Carbamazepine may interact with Divalproex sodium, potentially requiring dosage adjustments.
- **Warfarin (10%):** A smaller group of professionals consider Warfarin to potentially interact with Divalproex sodium.
- **Aspirin (14%):** Some professionals think Aspirin may interact with Divalproex sodium and require dosage adjustments.

17. In your clinical practice, how often would you consider switching from Divalproex to another drug therapy in case of suboptimal efficacy?

A. Frequently

B. Occasionally

C. Rarely

D. Never



- **Frequently (71%):** The majority of healthcare professionals would consider switching from Divalproex to another drug therapy frequently if suboptimal efficacy is observed.
- **Occasionally (19%):** A smaller group of professionals would consider switching occasionally in case of suboptimal efficacy.
- **Rarely (10%):** A few professionals would rarely consider switching from Divalproex in case of suboptimal efficacy.

18. According to your opinion, do you believe Divalproex could be considered as a first-line treatment for epilepsy?

A. Yes

B. No



- **Yes (52%):** A slight majority of healthcare professionals believe that Divalproex could be considered a first-line treatment for epilepsy.
- **No (48%):** Nearly half of professionals do not consider Divalproex as a first-line treatment for epilepsy.

19. **In your clinical practice, how often would you typically follow up with patients after initiating Divalproex?**

A. Weekly

B. Monthly

C. Quarterly



- **Weekly (57%):** The majority of healthcare professionals typically follow up with patients weekly after initiating Divalproex.
- **Monthly (43%):** A smaller group of professionals typically follow up monthly after starting Divalproex therapy.

20. According to your opinion, how would you rate the overall efficacy of Divalproex?

A. Very effective

B. Effective

C. Moderately effective

D. Non-effective



- **Very Effective (28%):** A smaller group of healthcare professionals rate Divalproex as very effective.
- **Effective (62%):** The majority of professionals rate Divalproex as effective.
- **Moderately Effective (10%):** A small group of professionals consider Divalproex moderately effective.

SUMMARY

This study explores the prescribing patterns, clinical practices, and opinions of healthcare professionals regarding Divalproex Sodium, a drug commonly used to treat epilepsy, mania, and migraine prophylaxis. The data reflects how clinicians approach treatment in different conditions, the frequency of prescriptions, and the effectiveness of Divalproex in various therapeutic settings.

Prevalence of Conditions Treated

Epilepsy (33%): A substantial portion of healthcare professionals prescribe Divalproex primarily for epilepsy. Epilepsy is a neurological disorder characterized by recurrent seizures, and Divalproex is commonly used to manage this condition.

Mania (48%): Divalproex is frequently prescribed for mania, which is an episode of abnormally elevated mood, commonly seen in bipolar disorder. Clinicians are more likely to use Divalproex to stabilize mood in patients with manic episodes.

Migraine Prophylaxis (19%): A smaller group of healthcare professionals use Divalproex as a preventive treatment for migraines, although it's not the first-line therapy for this purpose.

Prescription Practices

Monotherapy (90%): The vast majority of clinicians prefer using Divalproex as a monotherapy (single-drug therapy) for treating epilepsy. This suggests that Divalproex is highly effective when used alone for controlling seizures.

Combination Therapy (10%): Some clinicians use Divalproex in combination with other antiepileptic drugs (AEDs), which could be due to the complexity of some epilepsy cases or the need to address refractory seizures.

Effectiveness and Duration

Seizure Freedom (>75%) (76%): Most clinicians report that more than 75% of epileptic patients achieve seizure freedom with Divalproex monotherapy, emphasizing its high efficacy in seizure control.

Optimal Duration (6 Months) (81%): Many clinicians believe that six months is the ideal duration for Divalproex therapy when treating focal onset seizures (seizures originating from a specific brain region), after which a reassessment or change in treatment might be considered.

Epilepsy Types Treated

Absence Seizure (57%): Absence seizures, characterized by brief episodes of loss of consciousness, are the most common type of seizure treated with Divalproex.

Generalized Tonic-Clonic Seizure (24%): A smaller group of clinicians use Divalproex for generalized tonic-clonic seizures (grand mal seizures), which involve the entire brain and cause convulsions.

Effectiveness Compared to Other Antiepileptic Drugs

More Effective (90%): An overwhelming majority of clinicians find Divalproex more effective than other antiepileptic drugs, suggesting that it is a first-line choice for many patients, especially for absence seizures and focal seizures.

Side Effects Management

Dose Reduction (62%): The most common strategy for managing side effects is dose reduction, which can help mitigate adverse effects while maintaining therapeutic efficacy.

Discontinuation or Switching (19%): If side effects are severe or unmanageable, some clinicians opt to either discontinue Divalproex or switch to another medication, suggesting that side effects may sometimes outweigh the benefits for certain patients.

Laboratory Monitoring

Liver Function (33%) and Renal Function (48%): Regular monitoring of liver and renal function is essential, as Divalproex can cause liver toxicity or impact kidney function. This routine monitoring helps prevent severe adverse effects and ensures safe use of the drug.

Drug Interactions

Carbamazepine (76%): A significant portion of clinicians believe that Carbamazepine may interact with Divalproex, possibly requiring dosage adjustments due to potential pharmacokinetic interactions.

Switching Therapy for Suboptimal Efficacy

Frequently (71%): In cases where Divalproex fails to provide adequate efficacy, most clinicians will frequently consider switching to another drug therapy. This reflects the importance of finding the most effective therapy for controlling seizures.

First-Line Treatment Consideration

Yes (52%): Slightly more than half of clinicians believe Divalproex could be considered a first-line treatment for epilepsy, while the rest may consider other options based on patient characteristics or the severity of epilepsy.

Follow-Up Frequency

Weekly (57%): Most clinicians prefer to follow up weekly with patients after initiating Divalproex, which is crucial for monitoring side effects, efficacy, and patient adherence to therapy.

DISCUSSION

Based on the survey data, The survey reveals that Divalproex is a commonly prescribed medication in clinical practice for the management of epilepsy and mania, with a preference for its use as a monotherapy. It is particularly favored for treating absence seizures, where it is seen as more effective than many other antiepileptic drugs. Clinicians emphasize the importance of regular monitoring, especially of liver and renal functions, given the potential for side effects such as liver toxicity and renal impairment. Dose reduction is the most common strategy to manage side effects, but some clinicians may choose to discontinue or switch therapies if the side effects persist or worsen. While Divalproex is generally well-regarded for its efficacy, there is an acknowledgment that in some cases, suboptimal efficacy may necessitate switching to alternative therapies. Despite this, Divalproex remains a critical option for patients with epilepsy and mania, particularly for those who have not responded to other treatments. It underscores the importance of individualizing treatment plans based on patient needs, tolerance, and response.

CLINICAL RECOMMENDATIONS

Integration into Treatment Plans: Clinicians should continue to use Divalproex as a first-line treatment for epilepsy and mania, especially for patients with focal seizures or those experiencing manic episodes due to bipolar disorder.

Dosage and Monitoring: Adhering to the recommended starting dose and regularly monitoring liver and renal function is essential to ensure safe and effective use of Divalproex.

Side Effects Management: If side effects like dizziness, nausea, or weight gain occur, dose reduction should be considered first. If the side effects persist or are severe, alternative treatments should be explored.

Patient Education: Educating patients about possible side effects and the importance of regular monitoring will improve adherence and optimize therapeutic outcomes.

CONSULTANT OPINION

Expert consultants acknowledge Divalproex as an effective treatment for both epilepsy and mania, highlighting its significant role in managing absence seizures and focal onset seizures. They also emphasize its effectiveness in mania management within bipolar disorder, making it a valuable tool in clinical practice. Despite its current success, consultants recommend conducting further research to fully confirm Divalproex's broader applications, especially for other types of epilepsy. Additionally, there is a call for more studies to assess its long-term safety and the potential for improved patient outcomes, ensuring that its use remains optimal and well-supported by clinical evidence.

MARKET OPPORTUNITIES

Unmet Medical Needs: There is a gap in effective therapies for patients who do not respond well to other antiepileptic drugs or mood stabilizers, creating an opportunity for Divalproex to serve this underserved population.

Strong Prescription Adoption: With 90% of clinicians using Divalproex, there is a robust market demand, particularly in monotherapy for epilepsy, which suggests that the drug is highly trusted by healthcare professionals.

Patient Satisfaction and Effectiveness: High patient satisfaction levels and the reported effectiveness of Divalproex in treating epileptic seizures and mania further enhance its appeal in the market, making it a preferred choice among clinicians.

MARKET POSITIONING

Targeted Marketing to Clinicians: The marketing strategy for Divalproex should focus on its effectiveness and safety profile as key differentiators, positioning it as a preferred therapy for epilepsy and mania. The campaign should emphasize its proven ability to manage absence seizures and focal onset seizures, as well as its well-established role in managing mania in bipolar disorder. Marketing efforts should also include practical guidance on monitoring side effects and the importance of regular check-ups for patients on long-term therapy.

Educational Initiatives: Educational programs for clinicians are vital to ensure a thorough understanding of Divalproex's clinical applications and optimal use. These initiatives can include continuing medical education (CME) programs, workshops, and webinars that provide clinicians with the latest research on Divalproex's efficacy, safety, and new therapeutic uses. Additionally, peer-

reviewed publications could highlight real-world outcomes to support clinical decision-making.

Patient-Centric Approaches: A patient-centric marketing approach should highlight Divalproex's rapid onset of action and effectiveness in controlling seizures and mania, which can greatly improve the quality of life for patients. Patient education materials should focus on the treatment journey, explaining both the benefits and potential side effects. Real-world patient testimonials can be used to demonstrate how Divalproex has helped others with epilepsy or bipolar disorder, reinforcing its reliability and positive impact on everyday life.

Strategic Pricing and Access: To improve patient access to Divalproex, pricing strategies must align with both value proposition and affordability. Collaborations with insurance providers and healthcare systems should be prioritized to ensure that the drug is accessible to a broader patient base, particularly for long-term use. Ensuring that Divalproex is covered by insurance plans can increase its prescription rate, making it a go-to option for clinicians treating chronic conditions like epilepsy and mania.

Future Development: Future research should focus on enhancing the efficacy of Divalproex and ensuring long-term safety for patients. Developing new formulations or delivery methods, such as extended-release options, could help address unmet needs, especially for patients with resistant epilepsy or bipolar disorder. Research into comorbidities and personalized treatment plans could further optimize Divalproex's role in precision medicine.

Competitive Analysis: Ongoing competitive analysis is essential to position Divalproex effectively in the evolving market. By tracking emerging treatments and comparing efficacy and safety profiles, marketers can adapt strategies to maintain Divalproex's competitive edge. Understanding how new therapies

compare to Divalproex in terms of side effects, cost, and patient outcomes will help maintain its place as a leading choice for clinicians and patients alike.

REFERENCES

1. WHO. (2019). Epilepsy: A public health imperative. World Health Organization.
2. Kanner, A. M. (2011). The impact of epilepsy and its treatment on quality of life. CNS Drugs, 25(10), 933-946.
3. Brodie, M. J., & Yuen, A. W. (2000). Antiepileptic drug treatment: The optimal strategy for seizure control. Epilepsia, 41(5), 596-602.
4. Perucca, E., & Tomson, T. (2011). The pharmacological treatment of epilepsy. Lancet Neurology, 10(5), 446-456.
5. Löscher, W., & Potschka, H. (2005). Drug resistance in epilepsy. The Lancet Neurology, 4(5), 320-331.
6. Kanner, A. M., & Schaffer, D. (2002). The role of divalproex in the management of epilepsy. Epilepsy & Behavior, 3(6), 514-520.
7. Seizure, A. (2011). Divalproex sodium: A review of its therapeutic use in epilepsy. Seizure, 20(8), 509-518.
8. Meador, K. J., & Baker, G. A. (2006). Divalproex sodium and pregnancy: Reproductive effects and teratogenicity. Epilepsia, 47(2), 196-200.
9. Hauser, W. A., & Kurland, L. T. (2011). The epidemiology of epilepsy in the community: A review. Epilepsia, 52(1), 16-18.
10. Jacoby, A., & Baker, G. A. (2009). Quality of life in people with epilepsy: A review of the literature. Epilepsy & Behavior, 15(2), 138-144.

For the use or a Registered Medical Practitioner or a Hospital or a Laboratory only

Developed by:

Weston Medical Education Foundation of India

Office No: 99, 9th Floor, Kalpataru Avenue, Opp. ESIC Hospital,
Kandivali (East), Mumbai - 400101. M:9322615653. W:www.wmefi.co.in